These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2007-000290-32 A Multinational Double-Blind, Randomized Phase 2b Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Capecitabine in Patients with Locally ... 2010-11-30 due-trials
Completed, but no date, and reported results 2007-001428-11 Ensayo clínico multicéntrico, abierto, de Fase II con doxorubicina liposomal pegilada (Caelyx®) como tratamiento Primario en pacientes con cáncer de mama y antecedentes de Cardiopatía o con Edad supe... bad-data
Reported results 2011-006083-45 A phase II trial of BKM120 (a PI3K inhibitor) in patients with triple negative metastatic breast cancer Estudio fase II de BKM 120 (un inhibidor de PI3K) en pacientes con cáncer de mama triple nega... 2016-09-11 due-trials
Not reported 2012-000394-23 A Phase II, open-label, single-arm, exploratory pharmacogenomic study of single agent eribulin (HALAVEN®) as neoadjuvant treatment for operable Stage I-II HER2 non-overexpressing breast cancer 2015-10-21 due-trials
Reported results 2012-001201-24 A prospective, multicenter, single-arm, phase II study to evaluate the safety of neoadjuvant liposomal doxorubicin (Myocet®) plus paclitaxel, trastuzumab, and pertuzumab in patients with operable HE... 2016-01-18 due-trials
Completed, but no date, and reported results 2013-001036-22 PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in Stage I to IIIA HER2-positive breast cancer Fenotipo HER2-enriquecido determinado por la ... bad-data
Ongoing 2014-000793-19 A Phase II, Randomized Study of T DM1 versus T DM1 plus short induction with docetaxel in first line treatment for locally advanced or metastatic HER2+ breast cancer. Estudio fase II, aleatorizado,... not-yet-due
Ongoing 2014-005006-38 PATRICIA: A Phase II clinical trial of palbociclib and trastuzumab with or without letrozole in postmenopausal pretreated HER2-positive locally advanced or metastatic breast cancer patients PATRICI... not-yet-due
Reported results 2016-003098-17 CORALLEEN: A Phase 2 Clinical Trial of multi-agent Chemotherapy or letrozole plus Ribociclib (LEE001) as neoadjuvant treatment for postmenopausal patients with Luminal B/HER2-negative breast cancer. ... 2019-07-01 due-trials
Other 2018-003367-58 Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer, who have progressed on or after CDK 4/6 inhibitor t... not-yet-due
Not reported 2019-000710-11 Targeting EGFR/ERBB2 with Neratinib in Hormone Receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer (NEREA trial) Terapia con Neratinib dirigida a los receptores EGF... 2022-06-22 due-trials
Completed, but no date Terminated 2019-002806-28 TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER Ensayo con enzalutamida dirigido al subtipo Her2-enriquecido por PA... bad-data
Ongoing 2019-002991-15 HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos Ds8201-A-U301 y Ds8201-A-U302 HER2-PREDICT: Estudio Traslacional De Muestras De Tumor Procedentes De Los Ensayos D... not-yet-due
Ongoing 2020-000245-13 A Phase II with 2 parallel cohorts clinical trial targeting estrogen receptor negative or PAM50 non-luminal disease with Atezolizumab in combination with Trastuzumab and Vinorelbine in HER2-positive a... not-yet-due
Ongoing 2020-003022-22 EfficACy of Spartalizumab acROss multiPle cancer-types in patients with PD1-high mRNA expressing tumOrs defined by a singLe and pre-specIfied cutoff Eficacia de spartalizumab en múltiples tipos de ... not-yet-due
Completed, but no date Terminated 2020-003429-41 NiVOlumab for Luminal advanced/metastatic breast cancer to Taper ct-dnA In endocrine REsistance (VOLTAIRE trial) Nivolumab en el cáncer de mama luminal avanzado/metastásico para reducir el ADNtc en... bad-data
Ongoing 2021-001398-22 Predicting olaparib sensitivity in patients with unresectable locally advanced/metastatic HER2-negative breast cancer with BRCA1, BRCA2, PALB2, RAD51C or RAD51D mutations or RAD51-foci low test: RADIO... not-yet-due
Other 2021-002027-38 A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer - HARMONIA trial Estudio de fa... not-yet-due
Other 2021-002322-24 Neoadjuvant and adjuvant RIBOciclib and endocrine therapy for cLinicAlly high-RISk estrogen receptor-positive (ER+) and HER2-negative (HER2-) breast cancer (RIBOLARIS) not-yet-due
Ongoing 2022-001181-36 A phase 2 trial of neoadjuVAnt muLti-agENt chemotherapy or patritumab deruxtecan (HER3-DXd; HER3-DXd) with or without endocrINE therapy for high-risk HR+/HER2- breast cancer – VALENTINE trial Ensay... not-yet-due